Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States ( ) JAMA Intern Med. 2014;174(5): doi: /jamainternmed Trends in Treatment With Erythropoiesis-Stimulating Agents (ESAs) Prior to End-Stage Renal Disease (ESRD)A, Proportion of patients having received treatment with an ESA. B, Time from first recorded treatment with an ESA to ESRD (in days). Circles indicate median; error bars, interquartile range. C, Adjusted prevalence ratios of ESA use prior to ESRD (referent: 1995). Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid diabetes mellitus, estimated glomerular filtration rate, and body mass index at ESRD. Circles indicate prevalence ratio; error bars, 95% confidence interval. Figure Legend:

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States ( ) JAMA Intern Med. 2014;174(5): doi: /jamainternmed Trends in Treatment With Intravenous Iron Supplements Prior to End-Stage Renal Disease (ESRD)A, Proportion of patients receiving any intravenous iron supplementation. B, Specific intravenous iron formulation used in the earliest available claim. C, Adjusted prevalence ratios of intravenous iron use prior to ESRD (referent: 1995). Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid diabetes mellitus, estimated glomerular filtration rate, and body mass index at ESRD. Circles indicate prevalence ratio; error bars, 95% confidence interval. Figure Legend:

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States ( ) JAMA Intern Med. 2014;174(5): doi: /jamainternmed Trends in Blood Transfusion Use Prior to End-Stage Renal Disease (ESRD)A, Proportion of patients receiving any blood transfusion. B, Number of blood transfusion days. Compared with 2003 through 2006, the trend lines for transfusion use and number of transfusion days accelerated significantly in the period 2007 through 2010 (P <.001 and P =.04, respectively). C, Adjusted prevalence ratios of any blood transfusion prior to ESRD (referent: 1995). Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid diabetes mellitus, estimated glomerular filtration rate, and body mass index at ESRD. Circles indicate prevalence ratio; error bars, 95% confidence interval. Figure Legend:

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States ( ) JAMA Intern Med. 2014;174(5): doi: /jamainternmed Venn Diagrams of Use Among Anemia Treatments Prior to End-Stage Renal Disease (ESRD), 2010Numbers in circles correspond to percentage of patients who received the corresponding anemia treatment(s) in the 2 years prior to reaching ESRD. The number in the bottom right corner indicates the percentage of patients who did not receive any of the 3 treatments. ESA indicates erythropoiesis-stimulating agent. Figure Legend:

Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States ( ) JAMA Intern Med. 2014;174(5): doi: /jamainternmed Hemoglobin Concentration at Start of Therapy for End-Stage Renal Disease (ESRD)Circles indicate mean; error bars, 95% confidence interval. Figure Legend: